As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
REGULATORY
Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
Japan is mulling a pilot program for the Rx-to-OTC switching of emergency contraceptives, which would initially make these drugs available without a prescription at selected pharmacies. A health ministry panel will discuss this plan after the proposed switch drew overwhelming…
To read the full story
Related Article
REGULATORY
- Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
June 6, 2023
- Japan Likely to Approve Its 1st Cold Meds Containing Loxoprofen
June 6, 2023
- LDP Project Team Submits Proposal to Prime Minister
June 5, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…